Follicular Thyroid Cancer is an indication for drug development with over 20 pipeline drugs currently active. According to GlobalData, preregistered drugs for Follicular Thyroid Cancer have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Follicular Thyroid Cancer compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Follicular Thyroid Cancer overview

Follicular thyroid carcinoma is a cancer that forms in follicular cells of the thyroid. Follicular thyroid cancer constitutes 10 to 15% of all thyroid cancer cases, making it the second most common. Unlike differentiated types, undifferentiated types are rare. Diagnosis of follicular thyroid carcinoma relies on pathologic confirmation of follicular cells devoid of the nuclear atypia seen in papillary thyroid cancer, considering factors like capsular and vascular invasion. Evaluation primarily centers on histological findings, with controversy arising due to variations among pathologists. Treatment modalities for follicular thyroid carcinoma hinge on the stage at presentation. Minimally invasive cases undergo thyroid lobectomy and isthmectomy, while invasive cases necessitate total thyroidectomy, radioiodine ablation, and thyrotropin-suppressing medications. Studies highlight a 2.1-fold increase in recurrence for those skipping radioiodine ablation, reinforcing the standard recommendation of total thyroidectomy followed by radioiodine radiation.

For a complete picture of PTSR and LoA scores for drugs in Follicular Thyroid Cancer, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.